HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.

REFERENCES

1Lau CS, Mahendraraj K, Chamberlain RS. Hepatocellular carcinoma in the pediatric population: a population based clinical outcomes study involving 257 patients from the Surveillance, Epidemiology, and End Result (SEER) database (1973-2011). HPB Surg. 2015; 2015: 670728.
10.1155/2015/670728
PubMed Google Scholar
2Kelly D, Sharif K, Brown RM, Morland B. Hepatocellular carcinoma in children. Clin Liver Dis. 2015; 19: 433-447.
10.1016/j.cld.2015.01.010
PubMed Web of Science® Google Scholar
3Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterol J. 2013; 1: 351-357.
10.1177/2050640613501507
PubMed Web of Science® Google Scholar
4Allan BJ, Wang B, Davis JS, et al. A review of 218 pediatric cases of hepatocellular carcinoma. J Pediatr Surg. 2014; 49: 166-171; discussion 171.
10.1016/j.jpedsurg.2013.09.050
PubMed Web of Science® Google Scholar
5Meyers RL. Tumors of the liver in children. Surg Oncol. 2007; 16: 195-203.
10.1016/j.suronc.2007.07.002
CAS PubMed Web of Science® Google Scholar
6Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary Pancreat Dis Int. 2011; 10: 234-242.
10.1016/S1499-3872(11)60039-8
PubMed Web of Science® Google Scholar
7Austin MT, Leys CM, Feurer ID, et al. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. J Pediatr Surg. 2006; 41: 182-186.
10.1016/j.jpedsurg.2005.10.091
PubMed Web of Science® Google Scholar
8Schmid I, Haberle B, Albert MH, et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer. 2012; 58: 539-544.
10.1002/pbc.23295
PubMed Web of Science® Google Scholar
9Geissler EK, Schnitzbauer AA, Zulke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016; 100: 116-125.
10.1097/TP.0000000000000965
CAS PubMed Web of Science® Google Scholar
10Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol. 2002; 20: 2798-2804.
10.1200/JCO.2002.06.102
CAS PubMed Web of Science® Google Scholar
11Murawski M, Weeda VB, Maibach R, et al. Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies. J Clin Oncol. 2016; 34: 1050-1056.
10.1200/JCO.2014.60.2250
CAS PubMed Web of Science® Google Scholar
12Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Can Res. 2006; 66: 11851-11858.
10.1158/0008-5472.CAN-06-1377
CAS PubMed Web of Science® Google Scholar
13Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008; 61: 535-548.
10.1007/s00280-007-0639-9
CAS PubMed Web of Science® Google Scholar
14Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010; 304: 2154-2160.
10.1001/jama.2010.1672
CAS PubMed Web of Science® Google Scholar
15Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012; 18: 6011-6022.
10.1158/1078-0432.CCR-11-3284
CAS PubMed Web of Science® Google Scholar
16Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician's perspective. Semin Oncol. 2014; 41(Suppl 2): S1-S16.
10.1053/j.seminoncol.2014.01.001
PubMed Google Scholar
17Liu Y, Yue H, Xu S, et al. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol. 2015; 20: 952-959.
10.1007/s10147-015-0796-5
CAS PubMed Web of Science® Google Scholar
18Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008; 48: 1312-1327.
10.1002/hep.22506
CAS PubMed Web of Science® Google Scholar
19Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol. 2013; 30: 655.
10.1007/s12032-013-0655-z
CAS PubMed Web of Science® Google Scholar
20Granito A, Marinelli S, Terzi E, et al. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis. 2015; 47: 518-522.
10.1016/j.dld.2015.03.010
CAS PubMed Web of Science® Google Scholar
21Connell LC, Harding JJ, Abou-Alfa GK. Advanced hepatocellular cancer: the current state of future research. Curr Treat Options Oncol. 2016; 17: 43.
10.1007/s11864-016-0415-3
PubMed Web of Science® Google Scholar
22Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014; 312: 57-67.
10.1001/jama.2014.7189
CAS PubMed Web of Science® Google Scholar
23Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013; 59: 81-88.
10.1016/j.jhep.2013.02.022
CAS PubMed Web of Science® Google Scholar
24Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013; 19: 329-336.
10.1038/nm.3089
CAS PubMed Web of Science® Google Scholar
25Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther. 2011; 19: 1170-1179.
10.1038/mt.2011.39
CAS PubMed Web of Science® Google Scholar
26Geschwind JF, Gholam PM, Goldenberg A, et al. Use of transarterial chemoembolization (TACE) and sorafenib in patients with unresectable hepatocellular carcinoma: US regional analysis of the GIDEON registry. Liver Cancer. 2016; 5: 37-46.
10.1159/000367757
CAS PubMed Web of Science® Google Scholar
27Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci. 2013; 58: 3389-3396.
10.1007/s10620-013-2872-x
CAS PubMed Web of Science® Google Scholar
28Zhang Z, Liu Q, He J, Yang J, Yang G, Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer. 2000; 89: 2606-2612.
10.1002/1097-0142(20001215)89:12<2606::AID-CNCR13>3.0.CO;2-T
CAS PubMed Web of Science® Google Scholar
29Tan X, Zhang J, Wen Z, et al. Preoperative transcatheter arterial chemoembolization of hepatoblastoma in infants. J Vasc Interv Radiol. 2014; 25: 1029-1035.
10.1016/j.jvir.2014.03.032
PubMed Web of Science® Google Scholar
30Li JP, Chu JP, Yang JY, Chen W, Wang Y, Huang YH. Preoperative transcatheter selective arterial chemoembolization in treatment of unresectable hepatoblastoma in infants and children. Cardiovasc Intervent Radiol. 2008; 31: 1117-1123.
10.1007/s00270-008-9373-x
PubMed Web of Science® Google Scholar
31Malogolowkin MH, Stanley P, Steele DA, Ortega JA. Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol. 2000; 18: 1279-1284.
10.1200/JCO.2000.18.6.1279
CAS PubMed Web of Science® Google Scholar
32Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014; 14: 1205-1218.
10.1586/14737140.2014.949246
CAS PubMed Web of Science® Google Scholar
33Ismail H, Broniszczak D, Kalicinski P, et al. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant. 2009; 13: 682-692.
10.1111/j.1399-3046.2009.01062.x
CAS PubMed Web of Science® Google Scholar
34Bucuvalas JC, Ryckman FC. Long-term outcome after liver transplantation in children. Pediatr Transplant. 2002; 6: 30-36.
10.1034/j.1399-3046.2002.1r058.x
PubMed Web of Science® Google Scholar
35Reyes JD, Carr B, Dvorchik I, et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr. 2000; 136: 795-804.
10.1016/S0022-3476(00)44469-0
CAS PubMed Web of Science® Google Scholar
36Pham TA, Gallo AM, Concepcion W, Esquivel CO, Bonham CA. Effect of liver transplant on long-term disease-free survival in children with hepatoblastoma and hepatocellular cancer. JAMA Surg. 2015; 150: 1150-1158.
10.1001/jamasurg.2015.1847
PubMed Web of Science® Google Scholar
37McAteer JP, Goldin AB, Healey PJ, Gow KW. Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes. J Pediatr Surg. 2013; 48: 2194-2201.
10.1016/j.jpedsurg.2013.05.007
PubMed Web of Science® Google Scholar
38Waghray A, Balci B, El-Gazzaz G, et al. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2013; 27: 555-561.
10.1111/ctr.12150
CAS PubMed Web of Science® Google Scholar
39Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005; 56: 47-60.
10.1016/j.critrevonc.2004.09.009
PubMed Web of Science® Google Scholar
40Geissler EK, Schnitzbauer AA, Schlitt HJ. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: is this the end of the story? Liver Transpl. 2016; 22: 1162-1163.
10.1002/lt.24464
PubMed Web of Science® Google Scholar

Citing Literature

Volume21, Issue6

September 2017

e13007

Management of pediatric hepatocellular carcinoma: A multimodal approach

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Management of pediatric hepatocellular carcinoma: A multimodal approach

Abstract

REFERENCES

Citing Literature

References

Related

Information